StemCell Therapy

Breast cancer remains a major global healthcare concern despite exceptional levels of public awareness about the disease. A lack of clear causative environmental factors and hereditary dispositioning have resulted in the incidence of breast cancer continuing to rise, a trend which is expected to continue into the immediate future.

In the UK, breast cancer is the leading type of cancer in women, with there being over 54,900 cases diagnosed each year. Although early-stage cancer is relatively treatable and has good 5- and 10-year disease-free survival rates, 10% of cancers are diagnosed late. Additionally, there are no treatments for metastatic breast cancer, which ultimately results in death.

Get Free Sample PDF (Including Full TOC, Tables And Figures) of Market @https://www.researchmoz.us/enquiry.php?type=S&repid=1877885

As a whole, this presents a huge unmet clinical need in the breast cancer treatment algorithm. The treatment algorithm for breast cancer focuses on two main themes: standard chemotherapy and drugs that target hormones, namely estrogen and progesterone. However, chemotherapy and hormone drugs only make up a small percentage of the drug pipeline and an even smaller percentage of first-in-class products.

New trends in oncology are present in the breast cancer pipeline, in particular the focus on extracellular matrix degradation and improving the immune response to tumors. This report focuses on the epidemiology, pathophysiology and existing treatment options for breast cancer before giving detailed insight into promising pipeline targets and deal activity in the breast cancer market.

Scope

Unmet need is extremely high in late-stage breast cancer. What are the most important etiological risk factors and pathophysiological processes implicated in breast cancer? What is the current treatment algorithm? How effective are current therapies for these indications, and how does this impact prognosis? The breast cancer pipeline is large and contains a very high proportion of first-in-class product innovation. Which molecule types and molecular targets are most prominent across the breast cancer pipeline? What are the relationships between established and up-coming molecular targets in breast cancer? Which first-in-class targets are most promising? How does first-in-class target diversity differ by stage of development and molecular target class? The deals landscape is active and dominated by very high and very low deal values. Which indications attract the highest deal values? How has deal activity fluctuated over the past decade? Which first-in-class pipeline products have no prior involvement in licensing or co-development deals?

Enquiry For Discount or to Get Customized Report @https://www.researchmoz.us/enquiry.php?type=D&repid=1877885

Reasons to buy

Appreciate the current clinical and commercial landscapes by considering disease symptoms, pathogenesis, etiology, co-morbidities and complications, epidemiology, diagnosis, prognosis and treatment options. Identify leading products and key unmet needs within the market. Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target. Assess the therapeutic potential of first-in-class targets. Using proprietary matrix assessments, first-in-class targets in the pipeline have been assessed and ranked according to clinical potential. Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals, which may represent potential investment opportunities.

1 Table of Contents1 Table of Contents 21.1 List of Tables 41.2 List of Figures 42 Executive Summary 62.1 Exceptionally Large and Innovative Pipeline 62.2 Alignment of First-in-Class Molecular Target with Disease Causation 62.3 Highly Active Deals Landscape with Numerous Investment Opportunities 63 The Case for Innovation 73.1 Growing Opportunities for Biologic Products 73.2 Diversification of Molecular Targets 83.3 Innovative First-in-Class Product Developments Remain Attractive 83.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Innovation 93.5 Sustained Innovation in Breast Cancer 93.6 Report Guidance 94 Clinical and Commercial Landscape 114.1 Overview of Breast Cancer 114.2 Symptoms 114.3 Diagnosis 114.4 Etiology 124.4.1 Age and Gender 124.4.2 Genetics 124.4.3 Environmental 134.5 Pathophysiology 134.5.1 Tumor Initiation and Aberrant Cell Proliferation and Survival 134.5.2 Tumor Metabolic Shift 144.5.3 Tumor Progression, Micro-environment Alteration and Angiogenesis 154.5.4 Cancer Stem Cells 164.6 Epidemiology 164.7 Complications 174.8 Prognosis and Disease Staging 184.8.1 Classification 194.9 Introduction to Breast Cancer Treatments 204.9.1 Treatment Algorithm 204.9.2 Treatment Options for Breast Cancer 224.10 Overview of Marketed Products in Breast Cancer 264.11 Current Unmet Needs in the Breast Cancer Market 275 Assessment of Pipeline Product Innovation 295.1 Overview 295.2 Breast Cancer Pipeline by Phase of Development and Molecule Type 295.3 Pipeline by Molecular Target 305.4 Comparative Distribution of Programs between the Market and Pipeline by Molecular Target Class 325.5 Comparative Distribution of First-in-Class and Non-First-in-Class Pipeline Programs by Molecular Target Class 325.5.1 Percentage Distribution of First-in-Class and Non-First-in-Class Pipeline Programs 355.6 Ratio of First-In-Class Programs to First-in-Class Molecular Targets within the Pipeline 365.7 List of All First-in-Class Pipeline Programs 38

For More Information Kindly Contact:ResearchMozMr. Rohit Bhisey,Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email:[emailprotected]Follow us on LinkedIn @http://bit.ly/1TBmnVGMedia Release:https://www.researchmoz.us/pressreleaseFollow me on :http://marketresearchlatestreports.blogspot.com/

See the rest here:
Most Definitive & Accurate Study on Frontier Pharma: Breast Cancer First-in-Class Innovation Underlies Immunotherapeutic Potential and Pipeline...

This entry was posted on May 27, 2020 at 12:13 pm and is filed under Stem Cell Complications. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |